Arcutis Biotherapeutics Inc Aktie News

WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that on January 23, 2026, the Company and Kowa Pharmaceuticals America, Inc. mutually agreed to terminate their promotion agreement. The agreement covered sales ...

WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Wednesday, February 25, 2026 after the U.S. financial...

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effects Nearly 8 in 10 adults and parents agreed that their or their child's treatment plan focuses on reactively “taming a flare” rather than proactive long-term solutions When their skin condition is uncontrolled, nearly...

Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 million Advancement of ZORYVE indication-expansion strategy beginning with ongoing Phase 2 proof-of-concept trials in vitiligo and hidradenitis suppurativa Initiation of clinical development program for ARQ-234 in atopic dermatitis Transition to positive cash flows enables investment ...

New York City-based Suvretta Capital Management sold nearly 1.1 million ARQT shares during the third quarter. The move contributed to a decline in the overall position value by about $35.78 million.

Arcutis already has its key drug approved for various diseases and concentrations. Sales are expanding rapidly, and Arcutis is positioned for growth.

Arcutis today announced that Amit Munshi has been appointed to its BOD, and announced the retirement of founder and Board member Bhaskar Chaudhuri, PhD.

Arcutis Biotherapeutics has transitioned to profitability, driven by Zoryve's strong sales growth and market acceptance. Management projects Zoryve peak sales of $2.6B–$3.5B, far above Wall Street's $1.69B estimate, supporting a bullish outlook. ARQT's Q3 net income reached $7.4M, with cash flow break-even now expected in Q4, de-risking the investment case.